Acta Neuropathologica Communications

ANC: Neuroscience of Disease

Articles

Recent
Most accessed

Featured article: Multidimensional scaling of diffuse gliomas: Application to the 2016 WHO classification system with prognostically relevant molecular subtype discovery

Recent updating of the World Health Organization (WHO) classification of central nervous system (CNS) tumors in 2016 demonstrates the first organized effort to restructure brain tumor classification by incorporating histomorphologic features with recurrent molecular alterations. Here, the authors that molecular multidimensional scaling provides 2D clustering that represents the 2016 WHO classification of diffuse gliomas. Additionally, novel copy-number alteration-based molecular subtypes were identified and defined, which are independent of WHO grading, as well as predictive of clinical outcome

In this review, Witherspoon and Meilleur compile work published to date on the Ryanodine receptor isoform-1 (RyR1) pathway and to implicate potential regions as targets for treatment. Three of several RyR1 interacting proteins, FK506-binding protein 12 (FKBP12), triadin, and calmodulin, were identified as playing important roles across all groups and may serve as promising target sites for treatment.

Read this article

Editors-in-Chief

Werner Paulus, University of Münster, Germany
Johannes Attems, Newcastle University, UK

Aims and scope

Acta Neuropathologica Communications (ANC) focuses on the pathogenesis of neurological disease using experimental or human tissues, molecular, cellular, biological and morphological techniques.

Why publish with ANC?

No major revisions: only minor revisions are requested that can be performed (and have to be performed) within 3 weeks
Fast, thorough peer review: group of editors selected on the basis of their insightful, dedicated and prompt service
Rapid publication: publication within 2 months of submission
Inclusion in PubMed, PubMed Central and MEDLINE
Open access: enabling it to be read by a much larger set of readers, increasing its visibility
Competitive APC: flat article-processing charge, with no page limits, color figure charges or submission fees

Our commitment to excellent author service

ANC is committed to rapid publication. We aim to publish all research articles within 2 months of submission, subject to authors responding to requests within the required timeframe. If the publication of your article exceeds 2 months from submission, you may be entitled to a full waiver or discount of the article-processing charge on your next submission to the journal. This policy excludes manuscripts delayed for reasons outside of the Publisher's control, such as delays resulting from ethics-related issues or queries concerning your manuscript. All claims will be considered on a case-by-case basis. For further information or to make a claim, please contact editorial@actaneurocomms.org.

Sister journal

ANC is sister journal to Acta Neuropathologica, a journal dedicated to the pathology and mechanisms of neurological disease.

Visit Acta Neuropathologica

Tweets

Editors' quotes

"Acta Neuropathologica Communications is an open access, peer-reviewed online journal. Like our sister journal Acta Neuropathologica we focus on pathology and mechanisms of neurological disease. We publish high quality articles that do not require major manuscript revisions. We offer very fast turnaround times, publication of papers within two months following submission, enthusiastic editors, and a competitive article-processing charge. Try it out!"

Werner Paulus, co-Editor-in-Chief, ANC

"Acta Neuropathologica Communications is a journal for researchers working on human neurological disease and has a focus on neuropathology. However, since we believe that an interdisciplinary approach is highly valuable to advance the field, our journal is not restricted to classical neuropathological articles. Therefore, we also welcome high-quality submissions from other disciplines as long as they do ultimately aim to advance our understanding of human neurological disease. We try our best to help you with the submission process and in case of any questions do not hesitate to contact the Editors-in-Chief directly."

Johannes Attems, co-Editor-in-Chief, ANC